Intravenous immunoglobulin and hepatitis C virus: an overview of transmission episodes with emphasis on manufacturing data (Q36833823)

16 August 2017

1 reference

title

Intravenous immunoglobulin and hepatitis C virus: an overview of transmission episodes with emphasis on manufacturing data (English)

1 reference

16 August 2017

1 reference

Yap PL

1

1 reference

PubMed ID

8930441

16 August 2017

language of work or name

1 reference

1 January 1996

1 reference

16 August 2017

Clinical Therapeutics

1 reference

16 August 2017

18 Suppl B

1 reference

16 August 2017

43-58

1 reference

Non-A, non-B hepatitis from intravenous immunoglobulin

16 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Non-A, non-B hepatitis after intravenous gammaglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Transmission of non-A, non-B hepatitis by pH4-treated intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Long-term persistence of hepatitis C virus antibodies in a single source outbreak

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Hepatitis C virus antibodies in gammaglobulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

IgM production in hypogammaglobulinaemic patients during non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Inactivation of viruses in blood and plasma products

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Hepatitis C virus transmission by intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Detection by PCR of hepatitis C virus in factor VIII concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Demonstration of viraemia patterns in haemophiliacs treated with hepatitis-C-virus-contaminated factor VIII concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

HEPATITIS DUE TO THE INJECTION OF HOMOLOGOUS BLOOD PRODUCTS IN HUMAN VOLUNTEERS.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

The etiology of infectious hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Homologous serum jaundice; a problem in the operation of blood banks

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Safety of immune serum globulin with respect of homologous serum hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Prevention of Rh-immunization. Modified production of IgG anti-Rh for intravenous application by ion exchange chromatography (IEC).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Molecular epidemiology of an outbreak of infection with hepatitis C virus in recipients of anti-D immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

1 reference

7 January 2021

Asymptomatic hepatitis in adults given gamma-globulin for prophylaxis. Clinical and laboratory features

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Hepatitis B in subjects treated with a drug containing immunoglobulins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Epidemic hepatitis B caused by commercial human immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Transmission of hepatitis B by immune serum globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Letter: Acute hepatitis B after administration of gammaglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Hepatitis-B surface antigen in commercial gamma-globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Recovery of Australia antigen from human plasma products separated by a modified Cohn fractionation.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

HBs Antigen in Human Plasma Fractions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Intravenous administration of human gamma-globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Serum ALT levels in patients with primary hypogammaglobulinaemia receiving replacement therapy with intravenous immunoglobulin or fresh frozen plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Chronic hepatitis C after high-dose intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Gammagard and reported hepatitis C virus episodes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Infection with hepatitis C virus. Intravenous gammaglobulin may still infect patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Spurious outbreak of HCV in bone-marrow recipients treated with cytomegalovirus immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Testing for HCV-RNA in commercial intravenous immunoglobulins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Detection and characterization of hepatitis C virus RNA in immune globulins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Virus safety of human immunoglobulins: Efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Tolerability and kinetics of a solvent-detergent-treated intravenous immunoglobulin preparation in hypogammaglobulinaemia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Potential contribution of mild pepsin treatment at pH4 to the viral safety of human immunoglobulin products

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

Inactivation of hepatitis C virus in low pH intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

The viral safety of intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980195-0

7 January 2021

10.1016/S0149-2918(96)80195-0

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

8930441